Diagnostic Yield of Intranodal Forceps Biopsies in Mediastinal Adenopathy

Launched by GEORGE WASHINGTON UNIVERSITY · May 10, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at two different methods for diagnosing a condition called sarcoidosis, which can cause swelling in the lymph nodes located in the chest area. Researchers want to see which method—called endobronchial ultrasound transbronchial needle aspiration (EBUS-TBNA) or intranodal forceps biopsy (EBUS-IFB)—is better at correctly identifying this disease in patients who have enlarged lymph nodes.

To participate in the study, you must be at least 18 years old and have imaging results showing swelling in your lymph nodes, with a possible diagnosis of sarcoidosis reported by a healthcare professional. However, there are some health conditions that could prevent you from joining, such as severe lung problems or being unable to undergo anesthesia. If you decide to participate, you'll undergo one of the two biopsy procedures to help doctors understand your condition better. The study is currently recruiting participants, and everyone is welcome, regardless of gender.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Radiologic evidence of mediastinal and/or hilar lymphadenopathy
• • Attending radiologist or pulmonologist reports a possible diagnosis of sarcoidosis
• • Age 18 years or older
• Exclusion Criteria\*:
• • These are the characteristics that a participant must NOT have in order to be eligible to participate in the study.
• • Order Number Criteria
• • Severe pulmonary hypertension
• • Inability to undergo general anesthesia
• • Severe coagulopathy or bleeding diathesis
• • Previously diagnosed sarcoidosis
• • Patient presently taking clopidogrel
• • Patient deemed to be high risk for general anesthesia per anesthesiologist
• • Hemodynamic instability
• • Mediastinitis
• • Acute Hypercarbic Respiratory Failure (pCO2 \>55mmHg)